Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists

Neuroscience and Biobehavioral Reviews

Volumn 46, Issue P2, 2014, Pages 218-227

  Martínez Cué, Carmen ^a   Delatour, Benoît ^b   Potier, Marie Claude ^b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

Behavior; Convulsion; Down syndrome; Inverse agonist; 5 Subunit containing GABAA receptor; Aminobutyric acid

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; BILOBALIDE; CHLORIDE CHANNEL; NEUROTRANSMITTER; PENTETRAZOLE; PICROTOXIN; RO 4938581; UNCLASSIFIED DRUG; 3-BROMO-10-DIFLUOROMETHYL-9H-IMIDAZO(1,5-A)(1,2,4)TRIAZOLO(1,5-D)(1,4)BENZODIAZEPINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; BENZODIAZEPINE DERIVATIVE; IMIDAZOLE DERIVATIVE; NOOTROPIC AGENT; PWZ-029;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; CENTRAL NERVOUS SYSTEM; CHROMOSOME 21; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CONVULSION; DENTATE GYRUS; DOWN SYNDROME; GABAERGIC TRANSMISSION; HIPPOCAMPAL CA1 REGION; HYPERACTIVITY; LEARNING DISORDER; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NEUROMODULATION; NONHUMAN; RECEPTOR BINDING; REVIEW; SEIZURE; SYNAPTIC TRANSMISSION; ANIMAL; DRUG EFFECTS; HUMAN; INVERSE AGONISM; METABOLISM; NERVE CELL INHIBITION;

ANIMALS; BENZODIAZEPINES; DOWN SYNDROME; DRUG INVERSE AGONISM; GABA-A RECEPTOR ANTAGONISTS; HUMANS; IMIDAZOLES; NEURAL INHIBITION; NOOTROPIC AGENTS; PENTYLENETETRAZOLE; RECEPTORS, GABA-A;

EID: 84909642810     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.12.008     Document Type: Review

References (120)

1. Altafaj X., Martin E.D., Ortiz-Abalia J., Valderrama A., Lao-Peregrin C., Dierssen M., Fillat C. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2013, 52:117-127.
2. Atack J.R., Bayley P.J., Seabrook G.R., Wafford K.A., McKernan R.M., Dawson G.R. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology 2006, 51:1023-1029.
3. Atack J.R. Preclinical and clinical pharmacology of the GABA(A) receptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacol. Ther. 2010, 125:11-26.
4. A α5 subunit-containing receptors. Psychopharmacology 2009, 202:207-223.
5. Bartesaghi R., Guidi S., Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down syndrome?. Rev. Neurosci. 2011, 22:419-455.
6. Begenisic T., Spolidoro M., Braschi C., Baroncelli L., Milanese M., Pietra G., Fabbri M.E., Bonanno G., Cioni G., Maffei L., Sale A. Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome. Front. Cell Neurosci. 2011, 5:29.
7. Belichenko P.V., Masliah E., Kleschevnikov A.M., Villar A.J., Epstein C.J., Salehi A., Mobley W.C. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J. Comp. Neurol. 2004, 480:281-298.
8. Belichenko P.V., Kleschevnikov A.M., Masliah E., Wu C., Takimoto-Kimura R., Salehi A., Mobley W.C. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2009, 512:453-466.
9. Best T.K., Siarey R.J., Galdzicki Z. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J. Neurophysiol. 2007, 97:892-900.
10. Best T.K., Cramer N.P., Chakrabarti L., Haydar T.F., Galdzicki Z. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp. Neurol. 2012, 233:749-757.
11. Bhattacharyya A., McMillan E., Chen S.I., Wallace K., Svendsen C.N. A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells. Dev. Neurosci. 2009, 31:497-510.
12. Bianchi P., Ciani E., Contestabile A., Guidi S., Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2010, 20:106-118.
13. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
14. Bittles A.H., Bower C., Hussain R., Glasson E.J. The four ages of Down syndrome. Eur. J. Public Health 2007, 17:221-225.
15. Bonin R.P., Martin L.J., MacDonald J.F., Orser B.A. Alpha5GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J. Neurophysiol. 2007, 98:2244-2254.
16. Bonnert T.P., McKernan R.M., Farrar S., le Bourdelles B., Heavens R.P., Smith D.W., Hewson L., Rigby M.R., Sirinathsinghji D.J., Brown N., Wafford K.A., Whiting P.J. theta, a novel gamma-aminobutyric acid type A receptor subunit. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9891-9896.
17. Bortone D., Polleux F. KCC2 expression promotes the termination of cortical interneuron migration in a voltage-sensitive calcium-dependent manner. Neuron 2009, 62:53-71.
18. Braudeau J., Dauphinot L., Duchon A., Loistron A., Dodd R.H., Herault Y., Delatour B., Potier M.C. Chronic treatment with a promnesiant GABA-A alpha5-selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a down syndrome mouse model. Adv. Pharmacol. Sci. 2011, 2011:153218.
19. Braudeau J., Delatour B., Duchon A., Pereira P.L., Dauphinot L., de Chaumont F., Olivo-Marin J.C., Dodd R.H., Herault Y., Potier M.C. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 2011, 25:1030-1042.
20. Caraiscos V.B., Elliott E.M., You-Ten K.E., Cheng V.Y., Belelli D., Newell J.G., Jackson M.F., Lambert J.J., Rosahl T.W., Wafford K.A., MacDonald J.F., Orser B.A. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3662-3667.
21. Chakrabarti L., Best T.K., Cramer N.P., Carney R.S., Isaac J.T., Galdzicki Z., Haydar T.F. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat. Neurosci. 2010, 13:927-934.
22. Chambers M.S., Atack J.R., Carling R.W., Collinson N., Cook S.M., Dawson G.R., Ferris P., Hobbs S.C., O'Connor D., Marshall G., Rycroft W., Macleod A.M. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. J. Med. Chem. 2004, 47:5829-5832.
23. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 2006, 200:256-261.
24. Colas D., Valletta J.S., Takimoto-Kimura R., Nishino S., Fujiki N., Mobley W.C., Mignot E. Sleep and EEG features in genetic models of Down syndrome. Neurobiol. Dis. 2008, 30:1-7.
25. Colas D., Chuluun B., Warrier D., Blank M., Wetmore D.Z., Buckmaster P., Garner C.C., Heller H.C. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. Br. J. Pharmacol. 2013, 169:963-973.
26. Cole S.O. Effects of benzodiazepines on acquisition and performance: a critical assessment. Neurosci. Biobehav. Rev. 1986, 10:265-272.
27. Collinson N., Kuenzi F.M., Jarolimek W., Maubach K.A., Cothliff R., Sur C., Smith A., Otu F.M., Howell O., Atack J.R., McKernan R.M., Seabrook G.R., Dawson G.R., Whiting P.J., Rosahl T.W. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J. Neurosci. 2002, 22:5572-5580.
28. Collinson N., Atack J.R., Laughton P., Dawson G.R., Stephens D.N. An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology (Berl) 2006, 188:619-628.
29. Contestabile A., Greco B., Ghezzi D., Tucci V., Benfenati F., Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 2012, 123:348-361.
30. Corrales A., Martinez P., Garcia S., Vidal V., Garcia E., Florez J., Sanchez-Barcelo E.J., Martinez-Cue C., Rueda N. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J. Pineal Res. 2013, 54:346-358.
31. Costa A.C., Grybko M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci. Lett. 2005, 382:317-322.
32. Costa A.C., Scott-McKean J.J., Stasko M.R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008, 33:1624-1632.
33. Coussons-Read M.E., Crnic L.S. Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field. Behav. Genet. 1996, 26:7-13.
34. Crestani F., Keist R., Fritschy J.M., Benke D., Vogt K., Prut L., Bluthmann H., Mohler H., Rudolph U. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8980-8985.
35. Das I., Park J.M., Shin J.H., Jeon S.K., Lorenzi H., Linden D.J., Worley P.F., Reeves R.H. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci. Transl. Med. 2013, 5:201ra120.
36. A receptors enhances cognition. J. Pharmacol. Exp. Ther. 2006, 316:1335-1345.
37. del Cerro S., Jung M., Lynch G. Benzodiazepines block long-term potentiation in slices of hippocampus and piriform cortex. Neuroscience 1992, 49:1-6.
38. Dorow R., Horowski R., Paschelke G., Amin M. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 1983, 2:98-99.
39. Driscoll L.L., Carroll J.C., Moon J., Crnic L.S., Levitsky D.A., Strupp B.J. Impaired sustained attention and error-induced stereotypy in the aged Ts65Dn mouse: a mouse model of Down syndrome and Alzheimer's disease. Behav. Neurosci. 2004, 118:1196-1205.
40. Duka T., Curran H.V., Rusted J.M., Weingartner H.J. Perspectives on cognitive psychopharmacology research. Behav. Pharmacol. 1996, 7:401-410.
41. Earnheart J.C., Schweizer C., Crestani F., Iwasato T., Itohara S., Mohler H., Luscher B. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. 2007, 27:3845-3854.
42. Eng W., Atack J.R., Bergstrom M., Sanabria S., Appel L., Dawson G.R., Sciberras D., Hargreaves R.J., Langstrom B., Burns H.D. Occupancy of human brain GABA(A) receptors by the novel alpha5 subtype-selective benzodiazepine site inverse agonist alpha5IA as measured using [(1)(1)C]flumazenil PET imaging. Neuropharmacology 2010, 59:635-639.
43. Escorihuela R.M., Fernandez-Teruel A., Vallina I.F., Baamonde C., Lumbreras M.A., Dierssen M., Tobena A., Florez J. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 1995, 199:143-146.
44. Escorihuela R.M., Vallina I.F., Martinez-Cue C., Baamonde C., Dierssen M., Tobena A., Florez J., Fernandez-Teruel A. Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 1998, 247:171-174.
45. Faizi M., Bader P.L., Tun C., Encarnacion A., Kleschevnikov A., Belichenko P., Saw N., Priestley M., Tsien R.W., Mobley W.C., Shamloo M. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol. Dis. 2011, 43:397-413.
46. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., Garner C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413.
47. Fritschy J.M., Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 1995, 359:154-194.
48. Ge S., Goh E.L., Sailor K.A., Kitabatake Y., Ming G.L., Song H. GABA regulates synaptic integration of newly generated neurons in the adult brain. Nature 2006, 439:589-593.
49. Ghoneim M.M., Mewaldt S.P. Benzodiazepines and human memory: a review. Anesthesiology 1990, 72:926-938.
50. Glykys J., Mody I. Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA A receptor alpha5 subunit-deficient mice. J. Neurophysiol. 2006, 95:2796-2807.
51. Guzowski J.F., Timlin J.A., Roysam B., McNaughton B.L., Worley P.F., Barnes C.A. Mapping behaviorally relevant neural circuits with immediate-early gene expression. Curr. Opin. Neurobiol. 2005, 15:599-606.
52. Hanson J.E., Blank M., Valenzuela R.A., Garner C.C., Madison D.V. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J. Physiol. 2007, 579:53-67.
53. Haydar T.F., Reeves R.H. Trisomy 21 and early brain development. Trends Neurosci. 2012, 35:81-91.
54. Holtzman D.M., Santucci D., Kilbridge J., Chua-Couzens J., Fontana D.J., Daniels S.E., Johnson R.M., Chen K., Sun Y., Carlson E., Alleva E., Epstein C.J., Mobley W.C. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13333-13338.
55. Huang W., Galdzicki Z., van Gelderen P., Balbo A., Chikhale E.G., Schapiro M.B., Rapoport S.I. Brain myo-inositol level is elevated in Ts65Dn mouse and reduced after lithium treatment. Neuroreport 2000, 11:445-448.
56. Insausti A.M., Megias M., Crespo D., Cruz-Orive L.M., Dierssen M., Vallina I.F., Insausti R., Florez J. Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci. Lett. 1998, 253:175-178.
57. Jensen S., Kirkegaard L., Anderson B.N. Randomized clinical investigation of Ro 15-1788, a benzodiazepine antagonist, in reversing the central effects of flunitrazepam. Eur. J. Anaesthesiol. 1987, 4:113-118.
58. Klausberger T. GABAergic interneurons targeting dendrites of pyramidal cells in the CA1 area of the hippocampus. Eur. J. Neurosci. 2009, 30:947-957.
59. Kleschevnikov A.M., Belichenko P.V., Faizi M., Jacobs L.F., Htun K., Shamloo M., Mobley W.C. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J. Neurosci. 2012, 32:9217-9227.
60. Kleschevnikov A.M., Belichenko P.V., Gall J., George L., Nosheny R., Maloney M.T., Salehi A., Mobley W.C. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2012, 45:683-691.
61. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 2004, 24:8153-8160.
62. Krivanek J., McGaugh J.L. Effects of pentylenetetrazol on memory storage in mice. Psychopharmacologia 1968, 12:303-321.
63. Krivanek J.A. Facilitation of avoidance learning by pentylenetetrazol as a function of task difficulty, deprivation and shock level. Psychopharmacologia 1971, 20:213-229.
64. Kurt M.A., Kafa M.I., Dierssen M., Davies D.C. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 2004, 1022:101-109.
65. Laurie D.J., Wisden W., Seeburg P.H. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J. Neurosci. 1992, 12:4151-4172.
66. Lejeune J., Turpin R., Gautier M. Mongolism; a chromosomal disease (trisomy). Bull. Acad. Natl. Med. 1959, 143:256-265.
67. Lingford-Hughes A., Hume S.P., Feeney A., Hirani E., Osman S., Cunningham V.J., Pike V.W., Brooks D.J., Nutt D.J. Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J. Cereb. Blood Flow Metab. 2002, 22:878-889.
68. Lister R.G. The amnesic action of benzodiazepines in man. Neurosci. Biobehav. Rev. 1985, 9:87-94.
69. Little H.J., Nutt D.J., Taylor S.C. Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling. Br. J. Pharmacol. 1984, 83:951-958.
70. Lott I.T., Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010, 9:623-633.
71. Macdonald R.L., Olsen R.W. GABAA receptor channels. Annu. Rev. Neurosci. 1994, 17:569-602.
72. Martinez-Cue C., Baamonde C., Lumbreras M., Paz J., Davisson M.T., Schmidt C., Dierssen M., Florez J. Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 2002, 134:185-200.
73. Martinez-Cue C., Rueda N., Garcia E., Florez J. Anxiety and panic responses to a predator in male and female Ts65Dn mice, a model for Down syndrome. Genes Brain Behav. 2006, 5:413-422.
74. Martinez-Cue C., Martinez P., Rueda N., Vidal R., Garcia S., Vidal V., Corrales A., Montero J.A., Pazos A., Florez J., Gasser R., Thomas A.W., Honer M., Knoflach F., Trejo J.L., Wettstein J.G., Hernandez M.C. Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J. Neurosci. 2013, 33:3953-3966.
75. McNamara R.K., dePape G.E., Skelton R.W. Differential effects of benzodiazepine receptor agonists on hippocampal long-term potentiation and spatial learning in the Morris water maze. Brain Res. 1993, 626:63-70.
76. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 2005, 27:246-252.
77. Merschman S.A., Rose M.J., Pearce G.E., Woolf E.J., Schaefer B.H., Huber A.C., Musson D.G., Perry K.J., Rush D.J., Varsolona R.J., Matuszewski B.K. Characterization of the solubility of a poorly soluble hydroxylated metabolite in human urine and its implications for potential renal toxicity. Pharmazie 2005, 60:359-363.
78. Mitra A., Blank M., Madison D.V. Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome. Brain Res. 2012, 1440:1-8.
79. Mohler H., Fritschy J.M., Luscher B., Rudolph U., Benson J., Benke D. The GABAA receptors. From subunits to diverse functions. Ion Channels 1996, 4:89-113.
80. Mohler H. Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model. Biochem. Pharmacol. 2012, 84:994-999.
81. Nutt D.J., Besson M., Wilson S.J., Dawson G.R., Lingford-Hughes A.R. Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 2007, 53:810-820.
82. Olsen R.W., Bureau M., Khrestchatisky M., MacLennan A.J., Chiang M.Y., Tobin A.J., Xu W., Jackson M., Sternini C., Brecha N. Isolation of pharmacologically distinct GABA-benzodiazepine receptors by protein chemistry and molecular cloning. Adv. Biochem. Psychopharmacol. 1990, 46:35-49.
83. Olsen R.W., Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009, 56:141-148.
84. Perez-Cremades D., Hernandez S., Blasco-Ibanez J.M., Crespo C., Nacher J., Varea E. Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J. Neural. Transm. 2010, 117:445-455.
85. Petersen E.N., Jensen L.H., Honore T., Braestrup C. Differential pharmacological effects of benzodiazepine receptor inverse agonists. Adv. Biochem. Psychopharmacol. 1983, 38:57-64.
86. Pueschel S.M., Louis S., McKnight P. Seizure disorders in Down syndrome. Arch. Neurol. 1991, 48:318-320.
87. Rabow L.E., Russek S.J., Farb D.H. From ion currents to genomic analysis: recent advances in GABAA receptor research. Synapse 1995, 21:189-274.
88. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
89. Reynolds G.P., Warner C.E. Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. Neurosci. Lett. 1988, 94:224-227.
90. Ross M.H., Galaburda A.M., Kemper T.L. Down's syndrome: is there a decreased population of neurons?. Neurology 1984, 34:909-916.
91. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10:685-697.
92. Rudolph U., Mohler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 2006, 6:18-23.
93. Rueda N., Mostany R., Pazos A., Florez J., Martinez-Cue C. Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci. Lett. 2005, 380:197-201.
94. Rueda N., Florez J., Martinez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 2008, 433:22-27.
95. Rueda N., Florez J., Martinez-Cue C. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast. 2012, 2012:584071.
96. Salehi A., Faizi M., Colas D., Valletta J., Laguna J., Takimoto-Kimura R., Kleschevnikov A., Wagner S.L., Aisen P., Shamloo M., Mobley W.C. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 2009, 1:7ra17.
97. Saran N.G., Pletcher M.T., Natale J.E., Cheng Y., Reeves R.H. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum. Mol. Genet. 2003, 12:2013-2019.
98. Sarter M., Bruno J.P., Berntson G.G. Psychotogenic properties of benzodiazepine receptor inverse agonists. Psychopharmacology (Berl) 2001, 156:1-13.
99. Savic M.M., Clayton T., Furtmuller R., Gavrilovic I., Samardzic J., Savic S., Huck S., Sieghart W., Cook J.M. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Res. 2008, 1208:150-159.
100. Seabrook G.R., Easter A., Dawson G.R., Bowery B.J. Modulation of long-term potentiation in CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands. Neuropharmacology 1997, 36:823-830.
101. Seidl R., Cairns N., Singewald N., Kaehler S.T., Lubec G. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn. Schmiedebergs Arch. Pharmacol. 2001, 363:139-145.
102. Serwanski D.R., Miralles C.P., Christie S.B., Mehta A.K., Li X., De Blas A.L. Synaptic and nonsynaptic localization of GABAA receptors containing the alpha5 subunit in the rat brain. J. Comp. Neurol. 2006, 499:458-470.
103. Sherman S.L., Allen E.G., Bean L.H., Freeman S.B. Epidemiology of Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2007, 13:221-227.
104. Siarey R.J., Carlson E.J., Epstein C.J., Balbo A., Rapoport S.I., Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920.
105. Siarey R.J., Stoll J., Rapoport S.I., Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology 1997, 36:1549-1554.
106. Sieghart W., Eichinger A., Richards J.G., Mohler H. Photoaffinity labeling of benzodiazepine receptor proteins with the partial inverse agonist [3H]Ro 15-4513: a biochemical and autoradiographic study. J. Neurochem. 1987, 48:46-52.
107. Smigielska-Kuzia J., Sobaniec W. Brain metabolic profile obtained by proton magnetic resonance spectroscopy HMRS in children with Down syndrome. Adv. Med. Sci. 2007, 52(Suppl 1):183-187.
108. Smigielska-Kuzia J., Bockowski L., Sobaniec W., Kulak W., Sendrowski K. Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome. Pharmacol. Rep. 2010, 62:1070-1077.
109. Sternfeld F., Carling R.W., Jelley R.A., Ladduwahetty T., Merchant K.J., Moore K.W., Reeve A.J., Street L.J., O'Connor D., Sohal B., Atack J.R., Cook S., Seabrook G., Wafford K., Tattersall F.D., Collinson N., Dawson G.R., Castro J.L., MacLeod A.M. Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. J. Med. Chem. 2004, 47:2176-2179.
110. Sturgeon X., Gardiner K.J. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm. Genome 2011, 22:261-271.
111. Szemes M., Davies R.L., Garden C.L., Usowicz M.M. Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome. Mol. Brain 2013, 6:33.
112. Tischmeyer W., Grimm R. Activation of immediate early genes and memory formation. Cell Mol. Life Sci. 1999, 55:564-574.
113. Tozuka Y., Fukuda S., Namba T., Seki T., Hisatsune T. GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells. Neuron 2005, 47:803-815.
114. Veall R.M. The prevalance of epilepsy among mongols related to age. J. Ment. Defic. Res. 1974, 18:99-106.
115. Venault P., Chapouthier G., Simiand J., Dodd R.H., Rossier J. Enhancement of performance by methyl beta-carboline-3-carboxylate, in learning and memory tasks. Brain Res. Bull. 1987, 19:365-370.
116. Venault P., Chapouthier G. From the behavioral pharmacology of beta-carbolines to seizures, anxiety, and memory. ScientificWorldJournal 2007, 7:204-223.
117. Whiting P.J., Bonnert T.P., McKernan R.M., Farrar S., Le Bourdelles B., Heavens R.P., Smith D.W., Hewson L., Rigby M.R., Sirinathsinghji D.J., Thompson S.A., Wafford K.A. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann. N. Y. Acad. Sci. 1999, 868:645-653.
118. Whittle N., Sartori S.B., Dierssen M., Lubec G., Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007, 120:e1465-e1471.
119. Wishart J.G. Socio-cognitive understanding: a strength or weakness in Down's syndrome?. J. Intellect. Disabil. Res. 2007, 51:996-1005.
120. Yee B.K., Hauser J., Dolgov V.V., Keist R., Mohler H., Rudolph U., Feldon J. GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur. J. Neurosci. 2004, 20:1928-1936.